Pfizer, Inc. (NYSE:PFE)‘s stock had its “buy” rating reissued by investment analysts at BMO Capital Markets in a research note issued to investors on Friday. They presently have a $39.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would suggest a potential upside of 10.86% from the company’s current price.
Other equities research analysts have also issued research reports about the stock. UBS AG restated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research note on Monday, July 31st. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, July 17th. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. Finally, ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company. Pfizer presently has an average rating of “Hold” and an average target price of $38.48.
Shares of Pfizer (PFE) traded down $0.02 during mid-day trading on Friday, reaching $35.18. 15,045,100 shares of the company’s stock were exchanged, compared to its average volume of 15,315,141. Pfizer has a 52-week low of $30.51 and a 52-week high of $36.78. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.34 and a quick ratio of 1.06. The firm has a market cap of $209,697.67, a price-to-earnings ratio of 14.07, a P/E/G ratio of 2.49 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The firm’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.61 EPS. research analysts predict that Pfizer will post 2.59 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (PFE) Rating Reiterated by BMO Capital Markets” was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/13/pfizer-inc-pfe-rating-reiterated-by-bmo-capital-markets.html.
In other news, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 374,621 shares of company stock valued at $12,796,098. Insiders own 0.06% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in PFE. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer during the 2nd quarter worth $103,000. D. Scott Neal Inc. increased its stake in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the last quarter. Herndon Capital Management LLC acquired a new position in Pfizer in the 2nd quarter valued at $120,000. Finally, Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer in the 1st quarter valued at $121,000. Institutional investors own 69.10% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.